Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS

Inclusion Criteria: * Age up to 18 years old * With a diagnosis formally established of DLBCL or transformed straightaway follicular lymphoma or 3B grade follicular lymphoma or Burkitt-like lymphoma * Eligible to a treatment by immunochemotherapy like R-CHOP, R-ACVBP or R-CHOP like * First line of treatment * Being able to benefit from standard extension assessment ( Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and bone marrow biopsy with a bone marrow aspiration) * Written informed consent * Tumor biopsy used for diagnosis available Exclusion Criteria: * Patient who cannot receive polychemotherapy like R-CHOP, R-ACVBP, or R-CHOP like * Patient who cannot benefit from standard extension assessment and follow-up by with Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) * Pregnant or breast-feeding woman * Guardianship, curatorship * Patient who cannot follow the medical procedures of the study for geographic, social, psychological,linguistic or physical reasons